Pharmacogenomic predictors of drug response and choice in dyslipidemia and hypertension
Variance-stabilizing transformation corrects spurious pharmacogenetic associations introduced by biomarker scaling. Genetic variation informs drug choice for dyslipidemia and hypertension, but current polygenic scores provide only modest benefits in clinical application.
Authors
- Malathi S.I. Dona
- Samuel A. Lambert (ORCID: https://orcid.org/0000-0001-8222-008X)
- M. Inouye
- Fumihiko Takeuchi
- Norihiro Kato
- William W.H. Ho
Institutions
- Baker Heart and Diabetes Institute (AU)
- La Trobe University (AU)
- University of Cambridge (GB)
- British Heart Foundation (GB)
- National Center for Global Health and Medicine (JP)
- Health Data Research UK (GB)
- Melbourne Health (AU)
Publication Details
- Journal
- medRxiv
- Published
- 2026-01-30
- DOI
- https://doi.org/10.64898/2026.01.28.26345024
- Primary Topic
- Genetic Associations and Epidemiology
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- National Institute for Health and Care Research
- Department of Health and Social Care
- National Institutes of Health
- Economic and Social Research Council
- NIHR Cambridge Biomedical Research Centre